106 related articles for article (PubMed ID: 30606542)
1. Development, characterization and biological in vitro assays of paclitaxel-loaded PCL polymeric nanoparticles.
Abriata JP; Turatti RC; Luiz MT; Raspantini GL; Tofani LB; do Amaral RLF; Swiech K; Marcato PD; Marchetti JM
Mater Sci Eng C Mater Biol Appl; 2019 Mar; 96():347-355. PubMed ID: 30606542
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of folate-modified PLGA nanoparticles containing paclitaxel for ovarian cancer therapy.
Luiz MT; Abriata JP; Raspantini GL; Tofani LB; Fumagalli F; de Melo SMG; Emery FDS; Swiech K; Marcato PD; Lee R; Marchetti JM
Mater Sci Eng C Mater Biol Appl; 2019 Dec; 105():110038. PubMed ID: 31546359
[TBL] [Abstract][Full Text] [Related]
3. Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer.
Han S; Dwivedi P; Mangrio FA; Dwivedi M; Khatik R; Cohn DE; Si T; Xu RX
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):957-967. PubMed ID: 30892967
[TBL] [Abstract][Full Text] [Related]
4. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
Kim JE; Park YJ
Int J Nanomedicine; 2017; 12():645-658. PubMed ID: 28176896
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer.
Lv W; Cheng L; Li B
Chem Pharm Bull (Tokyo); 2015; 63(2):68-74. PubMed ID: 25451039
[TBL] [Abstract][Full Text] [Related]
7. [Preparation, characterization of paclitaxel-loaded Pluronic P105 polymeric micelles and in vitro reversal of multidrug resistant tumor].
Wang YZ; Fang XL; Li YJ; Zhang ZW; Han LM; Sha XY
Yao Xue Xue Bao; 2008 Jun; 43(6):640-6. PubMed ID: 18822969
[TBL] [Abstract][Full Text] [Related]
8. Novel Soluplus(®)-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines.
Bernabeu E; Gonzalez L; Cagel M; Gergic EP; Moretton MA; Chiappetta DA
Colloids Surf B Biointerfaces; 2016 Apr; 140():403-411. PubMed ID: 26780253
[TBL] [Abstract][Full Text] [Related]
9. Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma.
Pandey V; Gajbhiye KR; Soni V
Drug Deliv; 2015 Feb; 22(2):199-205. PubMed ID: 24467582
[TBL] [Abstract][Full Text] [Related]
10. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.
Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M
Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053
[TBL] [Abstract][Full Text] [Related]
11. Extremely long tumor retention, multi-responsive boronate crosslinked micelles with superior therapeutic efficacy for ovarian cancer.
Xiao W; Suby N; Xiao K; Lin TY; Al Awwad N; Lam KS; Li Y
J Control Release; 2017 Oct; 264():169-179. PubMed ID: 28847739
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
Danhier F; Lecouturier N; Vroman B; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
J Control Release; 2009 Jan; 133(1):11-7. PubMed ID: 18950666
[TBL] [Abstract][Full Text] [Related]
13. Characterization and in-vitro bioactivity evaluation of paclitaxel-loaded polyester nanoparticles.
López-Gasco P; Iglesias I; Benedí J; Lozano R; Blanco MD
Anticancer Drugs; 2012 Oct; 23(9):947-58. PubMed ID: 22713593
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-loaded PCL-TPGS nanoparticles: in vitro and in vivo performance compared with Abraxane®.
Bernabeu E; Helguera G; Legaspi MJ; Gonzalez L; Hocht C; Taira C; Chiappetta DA
Colloids Surf B Biointerfaces; 2014 Jan; 113():43-50. PubMed ID: 24060929
[TBL] [Abstract][Full Text] [Related]
15. A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Li R; Zhang Q; Wang XY; Chen XG; He YX; Yang WY; Yang X
Drug Res (Stuttg); 2014 Oct; 64(10):541-7. PubMed ID: 24443309
[TBL] [Abstract][Full Text] [Related]
16. PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation.
Jiang X; Xin H; Sha X; Gu J; Jiang Y; Law K; Chen Y; Chen L; Wang X; Fang X
Int J Pharm; 2011 Nov; 420(2):385-94. PubMed ID: 21920419
[TBL] [Abstract][Full Text] [Related]
17. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of polymeric pH-sensitive STEALTH® nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel.
Lundberg BB
Int J Pharm; 2011 Apr; 408(1-2):208-12. PubMed ID: 21296135
[TBL] [Abstract][Full Text] [Related]
20. Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer.
Liu Y; Ng Y; Toh MR; Chiu GNC
J Control Release; 2015 Dec; 220(Pt A):438-446. PubMed ID: 26551345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
